Aili Wang1, Chongke Zhong1, Zhengbao Zhu1, Tian Xu1, Yanbo Peng1, Tan Xu1, Hao Peng1, Chung-Shiuan Chen1, Jinchao Wang1, Zhong Ju1, Qunwei Li1, Deqin Geng1, Yingxian Sun1, Jianhui Zhang1, Xiaodong Yuan1, Jing Chen1, Yonghong Zhang2, Jiang He2. 1. From the Department of Epidemiology, School of Public Health, China (A.W., C.Z., Z. Z., Tan Xu, H.P., Y.Z.); Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Medical College of Soochow University, China (A.W., C.Z., Z. B., Tan Xu, H.P., Y.Z.); Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA (C.-S.C., J.C., J.H.); Department of Neurology, Affiliated Hospital of Nantong University, China (Tian Xu); Department of Neurology, Affiliated Hospital of North China University of Science and Technology, Hebei (Y.P.); Department of Neurology, Yutian County Hospital, China (J.W.); Department of Neurology, Kerqin District First People's Hospital of Tongliao City, China (Z.J.); Department of Epidemiology, School of Public Health, Taishan Medical College, China (Q.L.); Department of Neurology, Affiliated Hospital of Xuzhou Medical College, China (D.G.); Department of Neurology, First Affiliated Hospital of China Medical University, China (Y.S.); Department of Neurology, Tongliao Municipal Hospital, China (J.Z.); Department of Neurology, Kailuan General Hospital, China (X.Y.); and Department of Medicine, Tulane University School of Medicine, New Orleans, LA (J.C., J.H.). 2. From the Department of Epidemiology, School of Public Health, China (A.W., C.Z., Z. Z., Tan Xu, H.P., Y.Z.); Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Medical College of Soochow University, China (A.W., C.Z., Z. B., Tan Xu, H.P., Y.Z.); Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA (C.-S.C., J.C., J.H.); Department of Neurology, Affiliated Hospital of Nantong University, China (Tian Xu); Department of Neurology, Affiliated Hospital of North China University of Science and Technology, Hebei (Y.P.); Department of Neurology, Yutian County Hospital, China (J.W.); Department of Neurology, Kerqin District First People's Hospital of Tongliao City, China (Z.J.); Department of Epidemiology, School of Public Health, Taishan Medical College, China (Q.L.); Department of Neurology, Affiliated Hospital of Xuzhou Medical College, China (D.G.); Department of Neurology, First Affiliated Hospital of China Medical University, China (Y.S.); Department of Neurology, Tongliao Municipal Hospital, China (J.Z.); Department of Neurology, Kailuan General Hospital, China (X.Y.); and Department of Medicine, Tulane University School of Medicine, New Orleans, LA (J.C., J.H.). yhzhang@suda.edu.cn jhe@tulane.edu.
Abstract
BACKGROUND AND PURPOSE: Elevated galectin-3 has been associated with atherosclerosis and poor outcomes in patients with heart failure. However, it remains unclear whether galectin-3 has any effect on the poor outcomes of ischemic stroke. The aim of the present study was to examine the association between galectin-3 with poor outcomes among patients with acute ischemic stroke. METHODS: Serum galectin-3 was measured in 3082 patients with acute ischemic stroke. The primary outcome was a combination of death or major disability (modified Rankin Scale score, ≥3) at 3 months after stroke. RESULTS: Compared with the lowest quartile of galectin-3, multivariate adjusted odds ratios (95% confidence intervals) for the highest quartile of galectin-3 were 1.55 (1.15-2.09) for composite outcome, 2.10 (0.89-4.95) for death, and 1.43 (1.05-1.93) for major disability. The addition of galectin-3 to the conventional risk factors significantly improved prediction of the combined outcome of death or major disability in patients with ischemic stroke (net reclassification index, 18.9%; P<0.001; integrated discrimination improvement, 0.4%; P=0.001). CONCLUSIONS: Higher levels of serum galectin-3 were independently associated with increased risk of death or major disability after stroke onset, suggesting that galectin-3 may have prognostic value in poor outcomes of ischemic stroke.
BACKGROUND AND PURPOSE: Elevated galectin-3 has been associated with atherosclerosis and poor outcomes in patients with heart failure. However, it remains unclear whether galectin-3 has any effect on the poor outcomes of ischemic stroke. The aim of the present study was to examine the association between galectin-3 with poor outcomes among patients with acute ischemic stroke. METHODS: Serum galectin-3 was measured in 3082 patients with acute ischemic stroke. The primary outcome was a combination of death or major disability (modified Rankin Scale score, ≥3) at 3 months after stroke. RESULTS: Compared with the lowest quartile of galectin-3, multivariate adjusted odds ratios (95% confidence intervals) for the highest quartile of galectin-3 were 1.55 (1.15-2.09) for composite outcome, 2.10 (0.89-4.95) for death, and 1.43 (1.05-1.93) for major disability. The addition of galectin-3 to the conventional risk factors significantly improved prediction of the combined outcome of death or major disability in patients with ischemic stroke (net reclassification index, 18.9%; P<0.001; integrated discrimination improvement, 0.4%; P=0.001). CONCLUSIONS: Higher levels of serum galectin-3 were independently associated with increased risk of death or major disability after stroke onset, suggesting that galectin-3 may have prognostic value in poor outcomes of ischemic stroke.
Authors: Christina Hansen; Cristina Sastre; Zoe Wolcott; Matthew B Bevers; W Taylor Kimberly Journal: Int J Stroke Date: 2020-11-09 Impact factor: 6.948